Can Qalsody reduce ALS symptoms?

Written by Inês Martins, PhD |

A

Can Qalsody reduce ALS symptoms?

Category: Qalsody

Data spanning the VALOR clinical trial and its open-label extension part, which supported the U.S. approval of Qalsody for amyotrophic lateral sclerosis (ALS), have demonstrated that early treatment can slow the progression of ALS associated with SOD1 gene mutations and extend survival compared with a delayed treatment start. However, similar to other available ALS therapies, Qalsody is not expected to reverse or reduce symptoms that are already evident at treatment initiation.

Print This Page
Inês Martins, PhD avatar

About the Author

Inês Martins, PhD Inês holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, Inês won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.


Recommended reading